-
公开(公告)号：US20220096616A1
公开(公告)日：2022-03-31
申请号：US17378954
申请日：2021-07-19
申请人： CureVac AG
发明人： Marijke BARNER , Jochen PROBST , Thomas LANDER , Ingmar HOERR
IPC分类号： A61K39/00
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
-
公开(公告)号：US20170000871A1
公开(公告)日：2017-01-05
申请号：US15271122
申请日：2016-09-20
申请人： CureVac AG
发明人： Jochen PROBST , Ingmar HOERR , Thomas LANDER
CPC分类号： A61K39/0011 , A61K39/00 , A61K39/39 , A61K2039/53 , A61K2039/55516 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译： 本发明涉及包含至少一种RNA的活性（免疫刺激性）组合物，优选mRNA，编码能够在哺乳动物中引发（适应性）免疫应答的至少两种（优选不同的）抗原，其中抗原选自 PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）。 本发明还涉及包含活性（免疫刺激）组合物和使用活性（免疫刺激）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的疫苗， 治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。 最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。
-
公开(公告)号：US20160303210A1
公开(公告)日：2016-10-20
申请号：US15198456
申请日：2016-06-30
申请人： CureVac AG
发明人： Jochen PROBST , Ingmar HOERR , Thomas LANDER
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K39/00 , A61K39/39 , A61K2039/53 , A61K2039/55516 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
摘要翻译： 本发明涉及包含至少一种RNA（优选mRNA）的活性（免疫刺激性）组合物，其编码至少两种（优选不同的）能够在哺乳动物中引发（适应性）免疫应答的抗原，其中所述抗原选自组 由PSA（前列腺特异性抗原），PSMA（前列腺特异性膜抗原），PSCA（前列腺干细胞抗原）和STEAP（前列腺的六跨膜上皮抗原）组成。 本发明还涉及包含活性（免疫刺激）组合物和使用活性（免疫刺激）组合物（用于制备疫苗）和/或用于引发（适应性）免疫应答的疫苗的疫苗， 治疗前列腺癌（PCa），优选新辅助和/或激素难治性前列腺癌，以及与之相关的疾病或病症。 最后，本发明涉及试剂盒，特别涉及含有活性（免疫刺激）组合物和/或疫苗的试剂盒。
-
公开(公告)号：US20160346370A1
公开(公告)日：2016-12-01
申请号：US15145746
申请日：2016-05-03
申请人： CureVac AG
发明人： Marijke BARNER , Jochen PROBST , Thomas LANDER , Ingmar HOERR
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2039/57 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
-
公开(公告)号：US20160317636A1
公开(公告)日：2016-11-03
申请号：US15145540
申请日：2016-05-03
申请人： CureVac AG
发明人： Marijke BARNER , Jochen PROBST , Thomas LANDER , Ingmar HOERR
IPC分类号： A61K39/00
CPC分类号： A61K39/0011 , A61K2039/53 , A61K2039/57 , A61K2039/572 , A61K2039/575 , A61K2039/70
摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.
-
公开(公告)号：US20160166668A1
公开(公告)日：2016-06-16
申请号：US15048126
申请日：2016-02-19
申请人： CureVac AG
CPC分类号： A61K39/0011 , A61K48/00 , A61K2039/53 , C07K14/4727 , C07K14/705 , C12N9/0091 , C12N9/16 , C12N9/485 , C12N9/6424 , C12Y116/01 , C12Y301/03002 , C12Y304/17021 , C12Y304/21077
摘要： The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), STEAP (Six Transmembrane Epithelial Antigen of the Prostate), MUC1 (Mucin 1) and PAP (Prostatic acid phosphatase). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens and to the use of said composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of prostate adenocarcinoma, locally limited, locally advanced, metastatic, castration-resistant (hormone-refractory), metastatic castration-resistant and non-metastatic castration-resistant prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and/or the vaccine.
摘要翻译： 本发明涉及一种组合物，其包含编码能够在哺乳动物中引发（适应性）免疫应答的抗原组合的至少一种mRNA，其中所述抗原选自PSA（前列腺特异性抗原），PSMA（ 前列腺特异性膜抗原），PSCA（前列腺干细胞抗原），STEAP（前列腺的六个跨膜上皮抗原），MUC1（粘蛋白1）和PAP（前列腺酸性磷酸酶）。 本发明还涉及包含至少一种编码抗原组合的mRNA和用于所述组合物（用于制备疫苗）和/或用于引发用于治疗的（适应性）免疫应答的疫苗）的疫苗的疫苗 的前列腺癌（PCa），优选前列腺腺癌，局部限制的，局部晚期的，转移的，去阉割的（激素难治的），转移性去阉割抗性和非转移性去钙抗性前列腺癌，以及与之相关的疾病或病症。 最后，本发明涉及试剂盒，特别涉及含有组合物和/或疫苗的试剂盒。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.021 秒)
